medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 4

<< Back Next >>

Ann Hepatol 2015; 14 (4)

DNA methylation markers and serum α-fetoprotein level are prognostic factors in hepatocellular carcinoma

Jin-Ching L, Yao-Chung W, Cheng-Chung W, Pei-Yin S, Wen-Yi W, Yi-Chih C

Language: English
References: 31
Page: 494-504
PDF size: 186.93 Kb.


ABSTRACT

Introduction. Hypermethylation of relevant genes may affect the prognosis of patients with cancer. The purpose of this study was to analyze whether methylation of the promoter regions of cell cycle regulators as well as elevated α-Fetoprotein (AFP) levels are useful prognostic factors for patients with hepatocellular carcinoma (HCC). Material and methods. Nested methylation-specific PCR (nested-MSP) was used to analyze methylation status of the promoter regions of p15, p16, p21, p27, and ras-association domain family 1 (RASSF1A) genes in tumor specimens from 50 patients with HCC. Results. Promoter methylation was most common in the RASSF1A gene (96%), followed by the p16 gene (56%), the p21 gene (44%), the p15 gene (28%), and the p27 gene (2%). Patients with a serum AFP level ‹ 400 ng/mL and an unmethylated p21 promoter had a better prognosis than patients with a serum AFP level ≥ 400 ng/mL and a methylated p21 promoter (overall survival, p = 0.076; disease-free survival, p = 0.016). In addition, patients with full methylation of the promoter region of RASSF1A had a better prognosis than patients with a partially methylated or unmethylated RASSF1A promoter region if their serum AFP level was ≥ 400 ng/mL (overall survival, p = 0.028; disease-free survival, p = 0.078). Conclusion. A partially methylated or unmethylated RASSF1A promoter as well as elevated serum AFP level or methylation of p21 in addition to elevated serum AFP level might be associated with poor prognosis in patients with hepatocellular carcinoma.N


REFERENCES

  1. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.

  2. Kao JH, Chen DS. Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia. Liver Int 2005; 25: 696-703.

  3. Goto T, Mizukami H, Shirahata A, Sakata M, Saito M, Ishibashi K, Kigawa G, et al. Aberrant methylation of the p16 gene is frequently detected in advanced colorectal cancer. Anticancer Res 2009; 29: 275-7.

  4. Berg T, Steigen SE. DNA methylation in breast and colorectal cancer’. Mod Pathol 2008; 21: 1063-4.

  5. Wang Y, Yu Z, Wang T, Zhang J, Hong L, Chen L. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer 2007; 56: 289-94.

  6. Yeo W, Wong N, Wong WL, Lai PB, Zhong S, Johnson PJ. High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinoma. Liver Int 2005; 25: 266-72.

  7. Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004; 22: 4632-42.

  8. Teodoridis JM, Strathdee G, Brown R. Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. Drug Resist Updat 2004; 7: 267-78.

  9. Mann CD, Neal CP, Garcea G, Manson MM, Dennison AR, Berry DP. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007; 43: 979-92.

  10. Narimatsu T, Tamori A, Koh N, Kubo S, Hirohashi K, Yano Y, Arakawa T, et al. p16 promoter hypermethylation in human hepatocellular carcinoma with or without hepatitis virus infection. Intervirology 2004; 47: 26-31.

  11. Zhang C, Li Z, Cheng Y, Jia F, Li R, Wu M, Li K, et al. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res 2007; 13: 944-52.

  12. Zhang C, Guo X, Jiang G, Zhang L, Yang Y, Shen F, Wu M, et al. CpG island methylator phenotype association with upregulated telomerase activity in hepatocellular carcinoma. Int J Cancer 2008; 123: 998-1004.

  13. Kao JT, Chuah SK, Huang CC, Chen CL, Wang CC, Hung CH, Chen CH, et al. P21/WAF1 is an independent survival prognostic factor for patients with hepatocellular carcinoma after resection. Liver Int 2007; 27: 772-81.

  14. Ito Y, Matsuura N, Sakon M, Miyoshi E, Noda K, Takeda T, Umeshita K, et al. Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence. Hepatology 1999; 30: 90-9.

  15. Shiohara M, el-Deiry WS, Wada M, Nakamaki T, Takeuchi S, Yang R, Chen DL, et al. Absence of WAF1 mutations in a variety of human malignancies. Blood 1994; 84: 3781-4.

  16. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996; 85: 707-20.

  17. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor suppressor. J Cell Sci 2007; 120: 3163-72.

  18. Agathanggelou A, Honorio S, Macartney DP, Martinez A, Dallol A, Rader J, Fullwood P, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene 2001; 20: 1509-18.

  19. Burbee DG, Forgacs E, Zöchbauer-Müller S, Shivakumar L, Fong K, Gao B, Randle D, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691-9.

  20. Dammann R, Takahashi T, Pfeifer GP. The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas. Oncogene 2001; 20: 3563-7.

  21. Lo KW, Kwong J, Hui AB, Chan SY, To KF, Chan AS, Chow LS, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61: 3877-81.

  22. Di Gioia S, Bianchi P, Destro A, Grizzi F, Malesci A, Laghi L, Levrero M, et al. Quantitative evaluation of RASSF1A methylation in the non-lesional, regenerative and neoplastic liver. BMC Cancer 2006; 6: 89.

  23. Li X, Hui AM, Sun L, Hasegawa K, Torzilli G, Minagawa M, Takayama T, et al. p16INK4A hypermethylation is associated with hepatitis virus infection, age, and gender in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 7484-9.

  24. Lee S, Lee HJ, Kim JH, Lee HS, Jang JJ, Kang GH. Aberrant CpG island hypermethylation along multistep hepatocarcinogenesis. Am J Pathol 2003; 163: 1371-8.

  25. Wong IH, Lo YM, Yeo W, Lau WY, Johnson PJ. Frequent p15 promoter methylation in tumor and peripheral blood from hepatocellular carcinoma patients. Clin Cancer Res 2000; 6: 3516-21.

  26. Ko E, Kim Y, Kim SJ, Joh JW, Song S, Park CK, Park J, et al. Promoter hypermethylation of the p16 gene is associated with poor prognosis in recurrent early-stage hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2008; 17: 2260-7.

  27. Roman-Gomez J, Castillejo JA, Jimenez A, Gonzalez MG, Moreno F, Rodriguez M del C, Barrios M, et al. 5’ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99: 2291-6.

  28. Saelee P, Wongkham S, Chariyalertsak S, Petmitr S, Chuensumran U. RASSF1A Promoter Hypermethylation as a Prognostic Marker for Hepatocellular Carcinoma. Asian Pac J Cancer Prev 2010; 11: 1677-81.

  29. Chan KC, Lai PB, Mok TS, Chan HL, Ding C, Yeung SW, Lo YM. Quantitative analysis of circulating methylated DNA as a biomarker for hepatocellular carcinoma. Clin Chem 2008; 54: 1528-36.

  30. Shen L, Ahuja N, Shen Y, Habib NA, Toyota M, Rashid A, Issa JP. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst 2002; 94: 755-61.

  31. Zhang YJ, Ahsan H, Chen Y, Lunn RM, Wang LY, Chen SY, Lee PH, et al. High frequency of promoter hypermethylation of RASSF1A and p16 and its relationship to aflatoxin B1-DNA adduct levels in human hepatocellular carcinoma. Mol Carcinog 2002; 35: 85-92.




2020     |     www.medigraphic.com